A
Arthur DeCillis
Researcher at University of Pittsburgh
Publications - 12
Citations - 5927
Arthur DeCillis is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Chemotherapy. The author has an hindex of 7, co-authored 9 publications receiving 5707 citations.
Papers
More filters
Journal ArticleDOI
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Bernard Fisher,John Bryant,Norman Wolmark,Eleftherios P. Mamounas,Ann J. Brown,Edwin R. Fisher,D L Wickerham,Mirsada Begovic,Arthur DeCillis,André Robidoux,Richard G. Margolese,A B Cruz,James L. Hoehn,A W Lees,Nikolay V. Dimitrov,Harry D. Bear +15 more
TL;DR: Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology.
Journal ArticleDOI
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
Bernard Fisher,Arleen F. Brown,Eleftherios P. Mamounas,S. Wieand,André Robidoux,Richard G. Margolese,A B Cruz,Edwin R. Fisher,Wickerham Dl,Norman Wolmark,Arthur DeCillis,James L. Hoehn,A W Lees,N V Dimitrov +13 more
TL;DR: Preoperative therapy reduced the size of most breast tumors and decreased the incidence of positive nodes in women with primary breast cancer and should be considered for the initial management of breast tumors judged too large for lumpectomy.
Journal ArticleDOI
Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
Bernard Fisher,James J. Dignam,John Bryant,Arthur DeCillis,D. Lawrence Wickerham,Norman Wolmark,Joseph P. Costantino,C Redmond,Edwin R. Fisher,David M. Bowman,Luc Deschenes,Nikolay V. Dimitrov,Richard G. Margolese,André Robidoux,Henry Shibata,Jose J. Terz,Ahg Paterson,Merrill I. Feldman,William B. Farrar,James Evans,H. Lavina A. Lickley +20 more
TL;DR: The outcome of patients in the B-14 trial through 10 years of follow-up indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease, and questions arose about how long the observed benefit would persist.
Journal ArticleDOI
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Bernard Fisher,James J. Dignam,Birol Emir,John Bryant,Arthur DeCillis,Norman Wolmark,D. Lawrence Wickerham,Nikolay V. Dimitrov,Neil Abramson,James N. Atkins,Henry Shibata,Luc Deschenes,Richard G. Margolese +12 more
TL;DR: Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.
Journal ArticleDOI
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
B Fisher,Stewart J. Anderson,D L Wickerham,Arthur DeCillis,Nikolay V. Dimitrov,Eleftherios P. Mamounas,Norman Wolmark,R Pugh,James N. Atkins,Frederick J. Meyers,Neil Abramson,J Wolter,R Bornstein,L Levy,Edward H. Romond,V Caggiano,M Grimaldi,P Jochimsen,Peter J. Deckers +18 more
TL;DR: It was concluded that, outside of a clinical trial, dose-intensification of cyclophosphamide in an AC combination represents inappropriate therapy for women with primary breast cancer.